当前位置: X-MOL 学术J. Intern. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality.
Journal of Internal Medicine ( IF 11.1 ) Pub Date : 2010-10-01 , DOI: 10.1111/j.1365-2796.2010.02258.x
1
Affiliation  

OBJECTIVES To assess whether associations of circulating lipoprotein-associated phospholipase A₂ (Lp-PLA₂) with vascular disease are independent of other risk factors. METHODS Lp-PLA₂ activity and mass, lipids and other characteristics were measured at baseline in 19,037 individuals at high risk of vascular disease in a randomized trial of simvastatin with 5-year average follow-up. RESULTS Lp-PLA₂ activity and mass were correlated with each other (r = 0.56), lipids and other vascular risk factors. The moderate association of Lp-PLA₂ activity with occlusive coronary events (n = 2531) in analyses adjusted for nonlipid factors (hazard ratio per 1 SD [HR] 1.11, 95% CI 1.06-1.15) became nonsignificant after further adjustment for apolipoproteins (HR 1.02, 0.97-1.06). Such adjustment also attenuated HRs with Lp-PLA₂ mass from 1.08 (1.03-1.12) to 1.05 (1.01-1.09). By contrast, the HR with apolipoprotein-B100 of 1.15 (1.10-1.19) was only slightly attenuated to 1.14 (1.09-1.19) after further adjustment for apolipoprotein A₁ and Lp-PLA₂. Age- and sex-adjusted HRs for other cardiac events (n = 1007) with either Lp-PLA₂ activity or mass were about 1.20, but HRs reduced after adjustment for nonlipid factors (activity: 1.11, 1.04-1.18; mass: 1.08, 1.02-1.15). Adjusted HRs for ischaemic stroke (n = 900) were weak and nonsignificant and for nonvascular mortality (n = 1040) were 1.01 (0.94-1.09) with activity and 1.12 (1.05-1.19) with mass. Simvastatin reduced Lp-PLA₂ levels by about one-quarter, but simvastatin's vascular protection did not vary with baseline Lp-PLA₂ concentration. CONCLUSIONS Associations of Lp-PLA₂ with occlusive coronary events depend considerably on lipid levels, whereas those with other cardiac events appear to reflect confounding from cardiovascular medication and prior vascular disease.

中文翻译:

脂蛋白相关磷脂酶 A2 活性和质量与血管疾病和非血管死亡率的关系。

目的 评估循环脂蛋白相关磷脂酶 A2 (Lp-PLA2) 与血管疾病的关联是否独立于其他危险因素。方法 在一项平均随访 5 年的辛伐他汀随机试验中,在基线时测量了 19,037 名血管疾病高危个体的 Lp-PLA2 活性和质量、脂质和其他特征。结果 Lp-PLA2 活性和质量相互关联 (r = 0.56)、脂质和其他血管危险因素。Lp-PLA2 活性与闭塞性冠状动脉事件(n = 2531)的中度关联在针对非脂质因素(每 1 SD [HR] 的风险比 1.11,95% CI 1.06-1.15)进行调整的分析中,在进一步调整载脂蛋白(HR)后变得不显着1.02, 0.97-1.06)。这种调整还使 Lp-PLA2 质量的 HR 从 1.08 (1.03-1.12) 衰减到 1。05 (1.01-1.09)。相比之下,载脂蛋白 B100 为 1.15 (1.10-1.19) 的 HR 在进一步调整载脂蛋白 A1 和 Lp-PLA2 后仅略微减弱至 1.14 (1.09-1.19)。具有 Lp-PLA2 活性或质量的其他心脏事件(n = 1007)的年龄和性别调整 HR 约为 1.20,但在调整非脂质因素后 HR 降低(活性:1.11、1.04-1.18;质量:1.08、1.02 -1.15)。缺血性卒中 (n = 900) 的调整后 HR 较弱且不显着,非血管死亡率 (n = 1040) 的活动性为 1.01 (0.94-1.09),质量为 1.12 (1.05-1.19)。辛伐他汀将 Lp-PLA2 水平降低了约四分之一,但辛伐他汀的血管保护作用不随基线 Lp-PLA2 浓度而变化。结论 Lp-PLA2 与闭塞性冠状动脉事件的关联在很大程度上取决于脂质水平,
更新日期:2019-11-01
down
wechat
bug